To view this email as a web page, click here

   Home

Subscribe

Advertise

 

 

 

 

April 30, 2019

Today's Rundown

Featured Story

Lilly dumps phase 2 cancer drugs that survived previous cull

Eli Lilly revealed in its first-quarter earnings presentation that it is dumping a PI3K/mTOR dual inhibitor it was developing for use in combinations and prexasertib, the CHK1 inhibitor it picked up from Array BioPharma.

Top Stories

In-demand Zymeworks nabs Seattle Genetics R&D executive Josephson

Neil Josephson, former VP of clinical development at cancer biotech Seattle Genetics, has jumped ship to Zymeworks.

European universities fail to report results for 83% of trials

The vast majority of universities are failing to comply with EU rules on the reporting of clinical trial results, according to a registry analysis. 

[Sponsored] Emerging Biotechs are Here to Stay; CROs Models Will Permanently Change

The prominence of emerging biotech looms large on the drug development landscape. CROs continue to adjust their core competencies and cultural mindset to tailor services for specific biotech needs.

After beefy funding rounds, exosome-focused Codiak guns for $86M IPO

It’s had big names join its ranks and big backing from VCs; now, early-stage exosome biotech Codiak BioSciences wants in on the public market.

Alentis raises series A round to advance drug against novel liver disease target

Alentis Therapeutics has raised CHF 12.5 million ($12.2 million) to take an advanced liver disease drug toward clinical development. The series A tees a team led by ex-Ablynx CBO Markus Ewert up to advance a lead antibody against a previously undiscovered liver target. 

Vividion reels in $82M to push 3 lead programs toward the clinic

Vividion Therapeutics, a company looking to increase the number of proteins that small molecules can target, has raised $82 million to bring at least one of three programs through clinical proof of concept.

AstraZeneca signs on BenevolentAI for lung, kidney drug discovery work

AstraZeneca has tapped BenevolentAI to help bring artificial intelligence and machine learning to its drug discovery projects aimed at chronic kidney disease and idiopathic pulmonary fibrosis.

Resources

[Whitepaper] Agile Competitive Intelligence: A 3-Step Mobile Research Strategy

What is agile competitive intelligence, and how can help healthcare researchers stay ahead of the curve?

[Whitepaper] Now Companies Can Move Validated, Mission Critical Apps To The Cloud

Learn how the cloud can support the performance and security requirements for validated, mission-critical applications historically designed and implemented exclusively via on-premises deployment.

[Whitepaper] How the Internet of Things Creates Smarter Labs

Learn how cloud-connected IoT sensors are transforming operations in leading life science labs. Read our white paper “The Smart Lab”.

[Whitepaper] Personalized Test for Treatment Prediction in Depression

Total Brain Announces Personalized Test for Treatment Prediction in Depression with 80% Accuracy.

[Whitepaper] Observed Impact of Medication Price Transparency on Patients and Practices

Prescription price transparency technology is here – but is it making a difference? Find out HERE.

[Whitepaper] Redefining Your Value to Win Empowered Patients: Six Steps to Success

Every life sciences firm talks about patient-centricity, but are you doing what it takes to deliver?

[Whitepaper] Key Life Sciences Trends, 2019 and Beyond

The year’s biggest compliance and technology trends in life sciences. Learn about the latest trends impacting the biotech, medical device and pharmaceutical industries.

[Whitepaper] The New World of Allosteric Modulation: Another Shot on Goal

Learn how to utilize allosteric modulation to maximize its full potential in drug discovery programs. Download this white paper to learn more.

[Whitepaper] Advanced HDX-MS and Native-MS for Improved Biologic Candidate Selection and Development

Discussion of the potential for improving biologic drug development success through earlier, strategic application of advanced mass spectrometry, because currently, with most biologic drugs, including gene therapies, failures are realized in late-stage development, after substantial investment has been made in a candidate.

[Whitepaper] Workbench for Biomarker and Translational Research

Clinical trials and biomarker data from patients when unified, harmonized, and made searchable; is a rich, reliable and controlled resource for research. This paper sets out the requirements for a Translational and Biomarker Research Workbench for scientists using the experiences from use of Xbiom™ at BioPharma.

[Whitepaper] Meet Our Uncle: 12 Protein Stability Applications on One Platform

Download this whitepaper to learn more!

[Whitepaper] Flow Chemistry For Modern API Development & Manufacturing

Is Flow Chemistry right for your API Development?

[eBook] 2018 Weekly Compendium

The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry.

Events